Grabar Law Office is investigating claims against Erasca, Insulet, Power Solutions International, and PROCEPT BioRobotics for alleged breaches of fiduciary duties and misleading shareholders. The investigations focus on issues such as misleading statements about drug development and clinical data at Erasca, manufacturing defects and safety risks at Insulet, overstated sales prospects at Power Solutions, and inflated sales figures due to discount programs at PROCEPT. Shareholders who held shares before specified dates are encouraged to seek corporate reforms and damages at no cost. These investigations could lead to significant legal and financial consequences for the companies involved.
HR Chief is launching the CXO Summit on October 7-8, 2026, in London, targeting senior HR leaders like CHROs to address workforce transformation and organizational resilience. The event features panels on strategic HR roles, future skills, and buildi...
VINCI, a French public limited company, disclosed the total number of shares forming its capital and the total voting rights as of July 31, 2026. The company has 587,033,654 shares and the same number of theoretical voting rights, with 554,842,442 vo...
A new market report forecasts significant growth in the global advanced carbon materials sector through 2037, driven by rising demand in electric vehicles, renewable energy, aerospace, defense, and AI infrastructure. The report covers 16 material cat...
Kimberly-Clark reported Q2 earnings per share of $1.80, missing the expected $2.01, and revenue of $4.19 billion, slightly below the $4.22 billion forecast. The company lowered its growth expectations due to cautious consumer spending, a fire at a di...
Amgen is set to report its Q2 2026 earnings with analysts forecasting a 2.9% increase in revenue to about $9.45 billion, despite a projected 7% drop in earnings to $5.60 per share. The company benefits from strong sales of key drugs like Repatha, Tez...
